Abstract | BACKGROUND: PROCEDURE: From 11/2003 to 1/2011, 60 patients were enrolled on a pilot phase II protocol with newly diagnosed intermediate- or high-risk RMS at Memorial Sloan-Kettering Cancer Center. Induction therapy consisted of two cycles of I + C followed by three cycles of vincristine, doxorubicin, and cyclophosphamide. At week 13, 47 patients received definitive primary-site RT or post-operative RT with two concurrent cycles of I + C. Median RT dose was 50.4 Gy (range 30.6-50.4 Gy). Radiation-related toxicities were evaluated according to the Common Terminology Criteria for Adverse Events, version 3.0. RESULTS: Median age of the cohort was 9 years. With median follow-up of 32 months, 2.5 year actuarial local control was 89%. Among all patients, grades 3 and 4 dermatitis were observed in 11% and 4%, respectively. Among parameningeal, orbit, and other head/neck sites, rates of grades 3 and 4 mucositis were 20% and 10%, respectively. Among abdomen/pelvis sites, 12% developed grade 3 diarrhea and 6% developed grade 3 cystitis. No treatment breaks were necessary. CONCLUSIONS: Preliminary results of irinotecan and carboplatin administered with concurrent RT in intermediate- and high-risk RMS demonstrated favorable tolerability, efficacy, and local control. Reduced rates of acute grades 3-4 mucositis were observed when compared with historical results.
|
Authors | Kavita V Dharmarajan, Leonard H Wexler, Suzanne L Wolden |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 60
Issue 2
Pg. 242-7
(Feb 2013)
ISSN: 1545-5017 [Electronic] United States |
PMID | 22619050
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Copyright | Copyright © 2012 Wiley Periodicals, Inc. |
Chemical References |
- Irinotecan
- Carboplatin
- Camptothecin
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Camptothecin
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Carboplatin
(administration & dosage, adverse effects, therapeutic use)
- Chemoradiotherapy
(methods)
- Child
- Female
- Humans
- Irinotecan
- Male
- Pilot Projects
- Rhabdomyosarcoma
(therapy)
- Soft Tissue Neoplasms
(therapy)
|